Treatment of AML by inhibitors of NHR2 and/or RUNX1/ETO-tetramerization provides a therapy option with a unique mode of action.
[更多]
Treatment of AML by inhibitors of NHR2 and/or RUNX1/ETO-tetramerization provides a therapy option with a unique mode of action.
[更多]
Peripherally acting NMDAR antagonists as new anti-diabetic medication. Novel approach for the reduction of blood sugar levels without risk of hypoglycaemia.
[更多]